
The FDA is reviewing a regulatory application to add an asthma indication to Boehringer Ingelheim's chronic obstructive pulmonary disease treatment, tiotropium bromide.

The FDA is reviewing a regulatory application to add an asthma indication to Boehringer Ingelheim's chronic obstructive pulmonary disease treatment, tiotropium bromide.

AstraZeneca today announced that it has completed the strategic transaction to transfer the rights to Almirall's respiratory franchise to the company.

New guidelines prioritize treatment options and preventive therapies for reducing the risk of COPD exacerbations in at-risk patients.

Even though smoking can exacerbate respiratory conditions and limit the efficacy of their treatment, patients often purchase cigarettes while filling prescriptions for asthma or antihypertensive drugs at pharmacies.

The disease burden of smoking remains immense despite widespread tobacco cessation efforts.

Coaching patients with chronic obstructive pulmonary disease on relaxation techniques can improve their quality of life and even ease their symptoms.

Combining 2 classes of COPD medications leads to better outcomes for older adults with comorbid asthma.

Program featuring care transition pharmacists shown to reduce hospital readmissions, improve patient satisfaction.


A recent article suggests that comparing 2 or more observations of a patient's COPD symptoms over time can help clinicians learn why patients lose control of the disease.


Study finds higher risk of cardiovascular and cerebrovascular disease in COPD patients, suggests spread of inflammation may be a factor.

Hospitalization rates for chronic obstructive pulmonary disease were found to be lower in communities that have smoke-free policies.

COPD patients who engaged in any amount of moderate to vigorous physical activity after hospitalization had significantly reduced rates of readmission, according to the results of a new study.

COPD patients have a significantly increased risk of developing nonamnestic mild cognitive impairment, according to the results of a study carried out by researchers at the Mayo Clinic.


The FDA has approved Anoro Ellipta (GlaxoSmithKline and Theravance, Inc) for maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.

Although many COPD patients avoid exercise due to their breath-robbing condition, a new study finds that those who reported the most exercise and did not reduce their exercise level over time had the fewest hospitalizations for exacerbations.

Our round-up of the latest Rx products.

A 50-year-old male with a history of benign prostatic hyperplasia, chronic obstructive pulmonary disease, and type 2 diabetes mellitus is admitted for a laparoscopic colectomy. The patient's surgeon requests a pharmacy consultation to develop a multimodal, opioid-sparing pain control regimen.


COPD patients treated with N-acetylcysteine had significantly fewer exacerbations than patients treated with placebo, but more data is needed before the compound can be made an integral component of treatment guidelines.

OTC case studies involving oral ulcerations, fungal infections, immunizations for a patient receiving corticosteroid therapy, and dry mouth.

A study evaluating the safety of benzodiazepines and opioids in chronic obstructive pulmonary disease patients finds that low-dose opioids may be safe for treating breathlessness in patients with severe cases.

Medication use improved in COPD and asthma patients whose community pharmacists intervened to address a range of potential problems.